Here, we explain the facts behind several more of Robert F. Kennedy Jr.’s claims during his two Senate hearings as nominee ...

We expect Lilly to continue to grow faster than the market, and model 60% 2025 Lilly GLP-1 sales growth. Lilly gained 5 points in US prescription share in 2024, and Zepbound’s 56% share of new ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

He pointed out that certain stocks often experience significant drops after earnings reports, a trend he has observed ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

They're known to aid in blood sugar control and, now, weight loss — but, according to a sweeping new study, the popular GLP-1 ...

While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.

This is just a tiny glimpse of the data available to CivicScience clients. Discover more data. CivicScience has data on over ...

But one Cleveland Clinic expert is imploring executives not to look away. "Preventive measures are often neglected because they don't generate revenue, but they are incredibly important," Leslie Cho, ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...

DexCom (NASDAQ: DXCM) is a healthcare company that makes continuous glucose monitoring (CGM) devices, which help people track ...

Eli Lilly ( LLY 3.89%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...